Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Cancer Research
|
February 1, 1995
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells
I Brock, D R Hipfner, B S Nielsen, et al.
Cancer Research
|
June 1, 1990
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
P B Jensen, B S Sørensen, E J Demant, et al.
Cancer Research
|
July 23, 1999
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform
I Wessel, L H Jensen, P B Jensen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|
November 14, 1997
Transduction potential of human retroviruses in highly proliferating small-cell lung cancer cells as well as non-proliferating hematopoietic stem cells
J E Hansen, G J Gram, S D Nielsen, et al.
Anti-Cancer Drug Design
|
October 12, 2002
Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines
L Rothenborg-Jensen, H F Hansen, I Wessel, et al.
Sleep Medicine Reviews
|
May 13, 2021
Sleep in hospitalized children and adolescents: A scoping review
Jane Hybschmann, Martha K Topperzer, Line K Gjærde, et al.
Advances in Experimental Medicine and Biology
|
May 23, 1998
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines
C J van Moorsel, G Veerman, V W Ruiz van Haperen, et al.
Cancer Research
|
April 16, 1998
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines
M Sehested, I Wessel, L H Jensen, et al.
Oncogene
|
June 5, 2007
DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours
J Bartkova, Z Horejsí, M Sehested, et al.
Biochemical Pharmacology
|
May 2, 2001
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines
A M Bergman, B Munch-Petersen, P B Jensen, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Cancer Research
|
February 1, 1995
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells
I Brock, D R Hipfner, B S Nielsen, et al.
Cancer Research
|
June 1, 1990
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
P B Jensen, B S Sørensen, E J Demant, et al.
Cancer Research
|
July 23, 1999
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform
I Wessel, L H Jensen, P B Jensen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|
November 14, 1997
Transduction potential of human retroviruses in highly proliferating small-cell lung cancer cells as well as non-proliferating hematopoietic stem cells
J E Hansen, G J Gram, S D Nielsen, et al.
Anti-Cancer Drug Design
|
October 12, 2002
Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines
L Rothenborg-Jensen, H F Hansen, I Wessel, et al.
Sleep Medicine Reviews
|
May 13, 2021
Sleep in hospitalized children and adolescents: A scoping review
Jane Hybschmann, Martha K Topperzer, Line K Gjærde, et al.
Advances in Experimental Medicine and Biology
|
May 23, 1998
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines
C J van Moorsel, G Veerman, V W Ruiz van Haperen, et al.
Cancer Research
|
April 16, 1998
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines
M Sehested, I Wessel, L H Jensen, et al.
Oncogene
|
June 5, 2007
DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours
J Bartkova, Z Horejsí, M Sehested, et al.
Biochemical Pharmacology
|
May 2, 2001
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines
A M Bergman, B Munch-Petersen, P B Jensen, et al.
Page
of 10